Dominic Reynolds
CSO Remix Therapeutics
This is a bio again.
Seminars
• How can expanding the target space beyond the common splice modulators unlock new opportunities for targeting novel disease areas
• What strategies are enabling the design of chemically diverse scaffolds to overcome current limitations in the ligand design space
• Are we overdependent on nonsense-mediated decay and can reducing this reliance drive broaden therapeutic applicability of splice modulators
• What lessons can be drawn from recent investments and platform development to guide future innovation in RNA-targeted small molecules
• REM-422 is being developed by Remix Therapeutics for the treatment of ACC and AML/HRMDS
• REMaster™ platform identifies compounds that address undruggable high unmet medical need targets
• Next generation Remix drug discovery programs are enabled by a suite of biophysical assays and expand the scope of pharmacologically tractable splice modulator modalities
- REM-422 is being developed by Remix Therapeutics for the treatment of ACC and AML/HRMDS
- REMaster™ platform identifies compounds that address undruggable high unmet medical need targets
- Next generation Remix drug discovery programs are enabled by a suite of biophysical assays and expand the scope of pharmacologically tractable splice modulator modalities
